Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CYPERMETHRIN
Cross Vetpharm Group Limited
QP53AC08
CYPERMETHRIN
2.5 %w/v
Pour-on Solution
LM-Licensed Merchant
Bovine
Cypermethrin
Ectoparasiticide
Authorised
1999-10-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Ezeepour 2.5% w/v Pour on Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance Cypermethrin Technical (93% w/w; cis/trans isomers 50 : 50) 2.5% w/v For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Pour-on solution. An oily-based clear, pale yellow solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For control of lice and flies. 4.3 CONTRAINDICATIONS Do not treat calves under 7 days of age. Do not use in cases of hypersensitivity to the active substance. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS As per the special safety precautions to be taken by the person administering the product to animals listed below. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS Ezeepour should be administered in a well-ventilated area. Protective clothing, including rubber gloves, should be worn and any accidental splashes should be washed off immediately. Do not eat, drink or smoke when applying Ezeepour. Wash hands and any exposed skin immediately after application has finished. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) Occasionally, slight signs of discomfort may be observed in some cattle during the 48 hours following application. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/09/2013_ _CRN 7013356_ _page number: 1_ These side-effects are only temporary and have no long-term implications. 4.7 USE DURING PREGNANCY, LACTATION OR LAY The active has a low oral activity and very little transdermal abs Read the complete document